Top

Published in:

Open Access 01-11-2007 | Educational Feature

An introduction to biomarkers: applications to chronic kidney disease

Author: Kevin V. Lemley

Published in: Pediatric Nephrology | Issue 11/2007

Abstract

Diagnosis and management of chronic kidney disease (CKD) will be characterized in the future by an increasing use of biomarkers—quantitative indicators of biologic or pathologic processes that vary continuously with progression of the process. “Classical” biomarkers of CKD progression include quantitative proteinuria, the percentage of sclerotic glomeruli or fractional interstitial fibrosis. New candidate biomarkers (e.g., urinary proteomic patterns) are being developed based on both mechanistic and “shotgun” approaches. Validation of potential biomarkers in prospective studies as surrogate endpoints for hard clinical outcomes is often complicated by the long lag time to the ultimate clinical outcome (e.g., end-stage renal disease). The very dense data sets that result from shotgun approaches on small numbers of patients carry a significant risk of model overfitting, leading to spurious associations. New analytic methods can help to decrease this risk. It is likely that clinical practice will come to depend increasingly on multiplex (vector) biomarkers used in conjunction with risk markers in early diagnosis as well as to guide therapy.

Available only for authorised users

Hewitt SM, Dear J, Star RA (2004) Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol 15:1677–1689PubMed

Pisitkun T, Johnstone R, Knepper MA (2006) Discovery of urinary biomarkers. Mol Cell Proteomics 5:1760–1771PubMed

Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95

Eknoyan G, Hostetter T, Bakris GL, Hebert L, Levey AS, Parving HH, Steffes MW, Toto R (2003) Proteinuria and other markers of chronic kidney disease: a position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Am J Kidney Dis 42:617–622PubMed

Schmid H, Henger A, Cohen CD, Frach K, Grone HJ, Schlondorff D, Kretzler M (2003) Gene expression profiles of podocyte-associated molecules as diagnostic markers in acquired proteinuric diseases. J Am Soc Nephrol 14:2958–2966PubMed

Schwab K, Witte DP, Aronow BJ, Devarajan P, Potter SS, Patterson LT (2004) Microarray analysis of focal segmental glomerulosclerosis. Am J Nephrol 24:438–447PubMed

Schmid H, Henger A, Kretzler M (2006) Molecular approaches to chronic kidney disease. Curr Opin Nephrol Hypertens 15:123–129PubMed

Yasuda Y, Cohen CD, Henger A, Kretzler M, European Renal cDNA Bank (ERCB) Consortium (2006) Gene expression profiling analysis in nephrology: towards molecular definition of renal disease. Clin Exp Nephrol 10:91–98PubMed

Thongboonkerd V, Mcleish KR, Arthur JM, Klein JB (2002) Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int 62:1461–1469PubMed

10.

Pieper R, Gatlin CL, McGrath AM, Makusky AJ, Mondal M, Seonarain M, Field E, Schatz CR, Estock MA, Ahmed N, Anderson NG, Steiner S (2004) Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 4:1159–1174PubMed

11.

Ransohoff DF (2004) Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 4:309–314PubMed

12.

Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531–537PubMed

13.

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874PubMed

14.

Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572–577PubMed

15.

Rai AJ, Zhang Z, Rosenzweig J, Shih IM, Pham T, Fung ET, Sokoll LJ, Chan DW (2002) Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 126:1518–1526PubMed

16.

Johnston KC (1999) What are surrogate outcome measures and why do they fail in clinical research? Neuroepidemiology 18:167–173PubMed

17.

Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O (2002) Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995–1003PubMed

18.

Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O’Rourke M; Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators; CAFE steering committee and writing committee (2006) Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the conduit artery function evaluation (CAFE) study. Circulation 113:1213–1225PubMed

19.

Cooper R, Kaanders JH (2005) Biological surrogate end-points in cancer trials: potential uses, benefits and pitfalls. Eur J Cancer 41:1261–1266PubMed

20.

Cohen CD, Grone HJ, Grone EF, Nelson PJ, Schlondorff D, Kretzler M (2002) Laser microdissection and gene expression analysis on formaldehyde-fixed archival tissue. Kidney Int 61:125–132PubMed

21.

Schmid H, Cohen CD, Henger A, Schlondorff D, Kretzler M (2004) Gene expression analysis in renal biopsies. Nephrol Dial Transplant 19:1347–1351PubMed

22.

Efron B, Hastie T, Johnstone I, Tibshirani R (2004) Least angle regression. Ann Stat 32:407–499

23.

Roden JC, King BW, Trout D, Mortazavi A, Wold BJ, Hart CE (2006) Mining gene expression data by interpreting principal components. BMC Bioinformatics 7:194–216PubMedPubMedCentral

24.

Michiels S, Koscielny S, Hill C (2005) Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365:488–492PubMed

25.

Efron B, Tibshirani RJ (1993) An introduction to the bootstrap. Chapman & Hall, New York

26.

Sharma K, Lee S, Han S, Lee S, Francos B, McCue P, Wassell R, Shaw MA, RamachandraRao SP (2005) Two-dimensional fluorescence difference gel electrophoresis analysis of the urine proteome in human diabetic nephropathy. Proteomics 5:2648–2655PubMed

27.

Henger A, Kretzler M, Doran P, Bonrouhi M, Schmid H, Kiss E, Cohen CD, Madden S, Porubsky S, Grone EF, Schlondorff D, Nelson PJ, Grone HJ (2004) Gene expression fingerprints in human tubulointerstitial inflammation and fibrosis as prognostic markers of disease progression. Kidney Int 65:904–917PubMed

28.

Lemley KV, Abdullah I, Myers BD, Meyer TW, Blouch K, Smith WE, Bennett PH, Nelson RG (2000) Evolution of incipient nephropathy in type 2 diabetes mellitus. Kidney Int 58:1228–1237PubMed

29.

Myers BD, Boothroyd D, Olshen RA (1998) Angiotensin-converting enzyme inhibitor for slowing progression of diabetic and nondiabetic kidney disease. J Am Soc Nephrol 9 (Suppl 12):S66–S70PubMed

30.

Gretz N, Schock D, Sadick M, Pill J (2007) Bias and precision of estimated glomerular filtration rate in children. Pediatr Nephrol 22:167–169PubMed

31.

Mitsnefes MM, Kathman TS, Mishra J, Kartal J, Khoury PR, Nickolas TL, Barasch J, Devarajan P (2007) Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol 22:101–108PubMed

32.

Bohle A, Mackensen-Saen S, von Gise H, Grund KE, Wehrmann M, Batz C, Bogenschutz O, Schmitt H, Nagy J, Muller C (1990) The consequences of tubulo-interstitial changes for renal function in glomerulopathies. A morphometric and cytological analysis. Pathol Res Pract 186:135–144PubMed

33.

Basgen JM, Steffes MW, Stillman AE, Mauer SM (1994) Estimating glomerular number in situ using magnetic resonance imaging and biopsy. Kidney Int 45:1668–1672PubMed

34.

Gandhi M, Olson JL, Meyer TW (1998) Contribution of tubular injury to loss of remnant kidney function. Kidney Int 54:1157–1165PubMed

35.

Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H (1982) Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1:1430–1432PubMed

36.

Mogensen CE, Christensen CK (1984) Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311:89–93PubMed

37.

Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE (1997) Predictors of the progression of renal disease in the modification of diet in renal disease study. Kidney Int 51:1908–1919PubMed

38.

Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G (1998) Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Kidney Int 53:1209–1216PubMed

39.

Rudberg S, Dahlquist G (1996) Determinants of progression of microalbuminuria in adolescents with IDDM. Diabetes Care 19:369–371PubMed

40.

Gorman D, Sochett E, Daneman D (1999) The natural history of microalbuminuria in adolescents with type 1 diabetes. J Pediatr 134:333–337PubMed

41.

Lemley KV, Blouch K, Abdullah I, Boothroyd DB, Bennett PH, Myers BD, Nelson RG (2000) Glomerular permselectivity at the onset of nephropathy in type 2 diabetes mellitus. J Am Soc Nephrol 11:2095–2105PubMed

42.

Bazzi C, Petrini C, Rizza V, Arrigo G, Beltrame A, D’Amico G (1997) Characterization of proteinuria in primary glomerulonephritides. SDS-PAGE patterns: clinical significance and prognostic value of low molecular weight (“tubular”) proteins. Am J Kidney Dis 29:27–35PubMed

43.

Norden AGW, Scheinman SJ, Deschodt-Lanckman MM, Lapsley M, Nortier JL, Thakker RV, Unwin RJ, Wrong O (2000) Tubular proteinuria defined by a study of Dent’s (CLCN5 mutation) and other tubular diseases. Kidney Int 57:240–249PubMed

44.

Woo KT, Lau YK, Lee GS, Wei SS, Lim CH (1991) Pattern of proteinuria in IgA nephritis by SDS-PAGE: clinical significance. Clin Nephrol 36:6–11PubMed

45.

Woo KT, Lau YK, Wong KS, Chiang GS-C (2000) ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. Kidney Int 58:2485–2491PubMed

46.

Joachim GR, Cameron JS, Schwartz M, Becker EL (1964) Selectivity of protein excretion in patients with the nephrotic syndrome. J Clin Invest 43:2332–2346PubMedPubMedCentral

47.

Spahr CS, Davis MT, McGinley MD, Robinson JH, Bures EJ, Beierle J, Mort J (2001) Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry. I. Profiling an unfractionated tryptic digest. Proteomics 1:93–107PubMed

48.

Park MR, Wang EH, Jin DC, Cha JH, Lee KH, Yang CW, Kang CS, Choi YJ (2006) Establishment of a 2-D human urinary proteomic map in IgA nephropathy. Proteomics 6:1066–1076PubMed

49.

Oates JC, Varghese S, Bland AM, Taylor TP, Self SE, Stanislaus R, Almeida JS, Arthur JM (2005) Prediction of urinary protein markers in lupus nephritis. Kidney Int 68:2588–2592PubMedPubMedCentral

50.

Patari A, Forsblom C, Havana M, Taipale H, Groop PH, Holthofer H (2003) Nephrinuria in diabetic nephropathy of type 1 diabetes. Diabetes 52:2969–2974PubMed

51.

Zhou H, Yuen PST, Pisitkun T, Gonzales PA, Yasuda H, Dear JW, Gross P, Knepper MA, Star RA (2006) Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery. Kidney Int 69:1471–1476PubMedPubMedCentral

52.

Cattran DC, Pei Y, Greenwood CM, Ponticelli C, Passerini P, Honkanen E (1997) Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int 51:901–907PubMed

53.

Gansevoort RT, de Zeeuw D, de Jong PE (1993) Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease. Am J Kidney Dis 22:202–206PubMed

54.

D’Amico G, Bazzi C (2003) Pathophysiology of proteinuria. Kidney Int 63:809–825PubMed

55.

Hara M, Yanagihara T, Takada T, Itoh M, Matsuno M, Yamamoto T, Kihara I (1998) Urinary excretion of podocytes reflects disease activity in children with glomerulonephritis. Am J Nephrol 18:35–41PubMed

56.

Vogelmann SU, Nelson WJ, Myers BD, Lemley KV (2003) Urinary excretion of viable podocytes in health and renal disease. Am J Physiol 285:F40–F48

57.

Kriz W, Lemley KV (1999) The role of the podocyte in glomerulosclerosis. Curr Opin Nephrol Hypertens 8:489–497PubMed

58.

Lemley KV, Lafayette RA, Safai M, Derby G, Blouch K, Squarer A, Myers BD (2002) Podocytopenia and disease severity in IgA nephropathy. Kidney Int 61:1475–1485PubMed

59.

Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, Saunders TL, Dysko RC, Kohno K, Holzman LB, Wiggins RC (2005) Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 16:2941–2952PubMed

60.

Kim YH, Goyal M, Kurnit D, Wharram B, Wiggins J, Holzman L, Kershaw D, Wiggins R (2001) Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 60:957–968PubMed

61.

Szeto C, Lai KB, Chow KM, Szeto CY, Yip TW, Woo KS, Li PK, Lai FM (2005) Messenger RNA expression of glomerular podocyte markers in the urinary sediment of acquired proteinuric diseases. Clin Chim Acta 361:182–190PubMed

62.

Hara M, Yanagihara T, Kihara I, Higashi K, Fujimoto K, Kajita T (2005) Apical cell membranes are shed into urine from injured podocytes: a novel phenomenon of podocyte injury. J Am Soc Nephrol 16:408–416PubMed

63.

Avihingsanon Y, Phumesin P, Benjachat T, Akkasilpa S, Kittikowit V, Praditpornsilpa K, Wongpiyabavorn J, Eiam-Ong S, Hemachudha T, Tungsanga K, Hirankarn N (2006) Measurement of urinary chemokine and growth factor messenger RNAs: A noninvasive monitoring in lupus nephritis. Kidney Int 69:747–753PubMed

Title: An introduction to biomarkers: applications to chronic kidney disease
Author: Kevin V. Lemley
Publication date: 01-11-2007
Publisher: Springer Berlin Heidelberg
Published in: Pediatric Nephrology / Issue 11/2007
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-007-0455-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

An introduction to biomarkers: applications to chronic kidney disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2007

Retinoic acid enhances nephron endowment in rats exposed to maternal protein restriction

Severe acute renal failure in a child: a rare complication of anicteric leptospirosis

Risk factors for renal scarring in children and adolescents with lower urinary tract dysfunction

IgA nephropathy: what’s new?

Low birth weight, but not postnatal weight gain, aggravates the course of nephrotic syndrome

Posterior reversible encephalopathy syndrome in the pediatric renal population